While the ATM mutational status of these patients was not disclosed, this observation aligns with preclinical studies indicating that the loss or downregulation of ATM is synthetic lethal with PARP inhibitors in gastric and colorectal cancer cell lines (43, 44). This evidence concerns the gene ATM and colorectal cancer.